- Vascepa included in Consensus Statement by the American
Association of Clinical Endocrinologists and American College of
Endocrinology1
- Chinese Society of Cardiology updated Guidelines now
include Vascepa in its Prevention of Cardiovascular
Diseases
- Vascepa is now included in the treatment guidelines or
otherwise recommended for use by 13 medical associations worldwide
including Thrombosis Canada2-14
- HLS expects the Canadian Cardiovascular Society will
review and potentially update its lipid management guidelines in
2021
TORONTO, Jan. 28, 2021 /CNW/ - HLS Therapeutics Inc.
("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical
company focusing on central nervous system and cardiovascular
markets, announces new support from independent medical societies
for the use of Vascepa (icosapent ethyl) in reducing the risk of a
Major Adverse Cardiovascular Event (MACE).
In the recent Consensus Statement by the American Association
of Clinical Endocrinologists (AACE) and American College of
Endocrinology on the Management of Dyslipidemia and Prevention of
Cardiovascular Disease Algorithm 2020 executive
summary1, the AACE treatment algorithm recommends that
Vascepa should be added to a statin for any patient with
established atherosclerotic cardiovascular disease (ASCVD) or
diabetes with ≥2 ASCVD risk factors and triglycerides between 135
and 499 mg/dL to prevent cardiac events. In addition, on
January 21, 2021, it was announced
that the Chinese Society of Cardiology had included icosapent ethyl
in its updated Guidelines for Primary Prevention of Cardiovascular
Diseases for 2021 as published in the Chinese Journal of
Cardiovascular Diseases. The guideline authors include "icosapent
ethyl 2 grams twice a day (as studied in REDUCE-IT®) as a treatment
consideration to further lower ASCVD in the appropriate patient
population."15
Vascepa (icosapent ethyl) is now included in the treatment
guidelines or otherwise recommended for use by 13 medical
associations worldwide.2-14 These include American
Diabetes Association; American Heart Association; National Lipid
Association; American Association of Clinical Endocrinologists;
American College of Endocrinology; Endocrine Society; European
Society of Cardiology; European Atherosclerosis Society; Chinese
Society of Cardiology; Japan Circulation Society; Brazilian Society
of Cardiology; and Thrombosis Canada. HLS expects that the relevant
guidelines from the Canadian Cardiovascular Society will be
reviewed and may be updated in 2021.
"Cardiovascular disease remains the number one killer
worldwide1 and the inclusion of Vascepa in treatment
guidelines from leading medical associations across the globe
further validates the acceptance of this unique drug to reduce the
risk of a MACE in cardiac or diabetic patients," said Gilbert Godin, CEO of HLS. "Vascepa is a
first-in-its-class medication and with substantial clinical
evidence behind it, we believe that there is an urgent and genuine
need for the product in the Canadian market today."
ABOUT VASCEPA (ICOSAPENT ETHYL) CAPSULES
VASCEPA (icosapent ethyl) capsules are the first-and-only
prescription treatment comprised solely of the active ingredient,
icosapent ethyl, a unique form of eicosapentaenoic acid.
Vascepa was approved by Health Canada, was added to Health
Canada's Register of Innovative Drugs and benefits from data
protection for a term of eight years, as well as being the subject
of multiple issued and pending patents based on its unique
clinical profile. HLS in-licensed the exclusive rights to Vascepa
for the Canadian market from Amarin Corporation (NASDAQ:AMRN).
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a specialty pharmaceutical company
focused on the acquisition and commercialization of late-stage
development, commercial stage promoted and established branded
pharmaceutical products in the North American markets. HLS's focus
is on products targeting the central nervous system and
cardiovascular therapeutic areas. HLS's management team is composed
of seasoned pharmaceutical executives with a strong track record of
success in these therapeutic areas and at managing products in each
of these lifecycle stages. For more information, please visit:
www.hlstherapeutics.com
FORWARD LOOKING INFORMATION
This release includes forward-looking statements regarding
HLS and its business. Such statements are based on the current
expectations and views of future events of HLS's management. In
some cases the forward-looking statements can be identified by
words or phrases such as "may", "will", "expect", "plan",
"anticipate", "intend", "potential", "estimate", "believe" or the
negative of these terms, or other similar expressions intended to
identify forward-looking statements, including, among others,
statements with respect to HLS's pursuit of additional product and
pipeline opportunities in certain therapeutic markets, statements
regarding growth opportunities and expectations regarding financial
performance. The forward-looking events and circumstances discussed
in this release may not occur and could differ materially as a
result of known and unknown risk factors and uncertainties
affecting HLS, including risks relating to the specialty
pharmaceutical industry, risks related to the regulatory approval
process, economic factors and many other factors beyond the control
of HLS. Forward-looking statements and information by their nature
are based on assumptions and involve known and unknown risks,
uncertainties and other factors which may cause HLS's actual
results, performance or achievements, or industry results, to be
materially different from any future results, performance or
achievements expressed or implied by such forward-looking statement
or information. Accordingly, readers should not place undue
reliance on any forward-looking statements or information. A
discussion of the material risks and assumptions associated with
this release can be found in the Company's Annual Information Form
dated March 18, 2020 and Management's
Discussion and Analysis dated November 4,
2020, both of which have been filed on SEDAR and can be
accessed at www.sedar.com. Accordingly, readers should not place
undue reliance on any forward-looking statements or information.
Except as required by applicable securities laws, forward-looking
statements speak only as of the date on which they are made and HLS
undertakes no obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
REFERENCES
1.
|
Handelsman Y,
Jellinger PS, Guerin CK, et al. Consensus Statement by the American
Association of Clinical Endocrinologists and American College of
Endocrinology on the Management of Dyslipidemia and Prevention of
Cardiovascular Disease Algorithm - 2020 Executive Summary. Endocr
Pract. 2020;26(10):1196-1224. doi:10.4158/CS-2020-0490
|
2.
|
American Diabetes
Association
http://main.diabetes.org/dorg/bod/2019-2020/ADA-Strategic-Architecture.pdf
|
3.
|
Kimura K, et al. Circ
J. 2019;83:1085 -1196
|
4.
|
American Heart
Association https://www.heart.org
|
5.
|
European Society of
Cardiology https://www.escardio.org/The-ESC/Who-we-are
|
6.
|
European
Atherosclerosis Society
https://www.eas-society.org/page/about_eas
|
7.
|
National Lipid
Association https://www.lipid.org/about
|
8.
|
American Association
of Clinical Endocrinologists
https://www.aace.com/disease-stateresources/diabetes/clinical-practice-guidelines-treatment-algorithms/comprehensive
|
9.
|
Brazilian Society of
Cardiology Cardiovascular Prevention Guideline Update
http://publicacoes.cardiol.br/portal/abc/ingles/aop/2019/aop-diretriz-prevencao-cardiovascular-ingles.pdf
|
10.
|
The Thrombosis
CanadaTM Clinical Guides. Stroke: Secondary Prevention. Accessed on
April 13, 2020. URL:
https://thrombosiscanada.ca/clinicalguides/#
|
11.
|
Vargas-Uricoechea H,
et al. Revista ACE. 2020;7(1):4-36,
http://revistaendocrino.org/index.php/rcedm
|
12.
|
Arnold SV, Bhatt DL,
Barsness GW, et al; on behalf of the American Heart Association
Council on Lifestyle and Cardiometabolic Health and Council on
Clinical Cardiology. Clinical management of stable coronary artery
disease in patients with type 2 diabetes mellitus: a scientific
statement from the American Heart Association. Circulation.
2020;141:e000–e000. doi: 10.1161/CIR.0000000000000766
|
13.
|
Collet JP, et al.
EHJ, ehaa575, https://doi.org/10.1093/eurheartj/ehaa575.
|
14.
|
Newman C, Blaha MJ,
Boord JB, Cariou B, Chait A, Fein H, Ginsberg H, Goldberg I, Murad
MH, Subramanian S, Tannock LR. Lipid Management in Patients with
Endocrine Disorders: An Endocrine Society Clinical Practice
Guideline. J Clin Endocrinol Metab. 2020 Sep 19:dgaa674. doi:
10.1210/clinem/dgaa674. Epub ahead of print. PMID: 32951056. Dated
Oct 29, 2020
|
15.
|
Cardiology Committee
of the National Medical Association, et al. Guidelines for Primary
Prevention of Cardiovascular Diseases in China. Chinese Journal of
Cardiovascular Diseases. 2020;48(12):1000-1038.
|
SOURCE HLS Therapeutics Inc.